Trial reportInternational journal of hematology2009
Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease.
Trial report in International journal of hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Alteration of naïve and memory B-cell subset in chronic graft-versus-host disease patients after treatment with mesenchymal stromal cells.Stem cells translational medicine · 2014Trial
- The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.Haematologica · 2011Trial
- Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study.Haematologica · 2010Trial
- Chronic graft-versus-host disease myelitis successfully treated with rituximab.International journal of hematology · 2025Article
- Cutaneous Chronic Graft-Versus-Host Disease: Clinical Manifestations, Diagnosis, Management, and Supportive Care.Transplantation and cellular therapy · 2024Review
- Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.Blood advances · 2023Article
- Chronic graft-vs-host disease: Current understanding of disease and treatment landscape.Journal of managed care & specialty pharmacy · 2022Article
- Chronic Graft-Versus-Host-Disease-Related Polymyositis: a 17-Months-Old Child with a Rare and Late Complication of Haematopoietic Stem Cell Transplantation.Mediterranean journal of hematology and infectious diseases · 2020Article
- Adverse events in second- and third-line treatments for acute and chronic graft-Therapeutic advances in hematology · 2020Review
- B cell depletion treatment decreases CD4+IL4+ and CD4+CD40L+ T cells in patients with systemic sclerosis.Rheumatology international · 2019Article
- Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Article
- The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease.Biomedicines · 2017Review
- Prophylactic and therapeutic treatment of graft-versus-host disease in Japan.International journal of hematology · 2015Review
- Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.The Journal of clinical investigation · 2014Article
- Novel applications of Rituximab in dermatological disorders.Indian dermatology online journal · 2014Review
- Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten.Haematologica · 2013Article
- Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options.Bone marrow transplantation · 2012Review
- Immunohistochemistry of affected tissue may guide cGVHD treatment decisions.Bone marrow transplantation · 2012Article
- Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease.Haematologica · 2012Article
- Graft-versus-host disease: part II. Management of cutaneous graft-versus-host disease.Journal of the American Academy of Dermatology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We prospectively evaluated the safety and efficacy of the anti-CD20 chimeric monoclonal antibody rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. Seven patients were treated with 375 mg/m(2) rituximab weekly for 4 consecutive weeks. Rituximab was well tolerated with no severe toxicity observed during treatment. At 1 year, 3 patients showed a partial response to rituximab therapy, 3 had stable disease, and 1 had progressive disease. Rituximab allowed a reduction in the dose of steroids in 4 patients. Responsive manifestations included mild to moderate skin and oral lesions, and immune hemolytic anemia, and thrombocytopenia. Severe manifestations involving the skin, fascia, and eye did not respond to treatment. These observations suggest that rituximab therapy may be effective for select patients with corticosteroid-refractory chronic GVHD that is not advanced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.